Evotec SE (NASDAQ:EVO - Free Report) - HC Wainwright increased their Q2 2025 earnings per share estimates for Evotec in a research report issued on Wednesday, May 7th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.05) for the quarter, up from their prior estimate of ($0.06). The consensus estimate for Evotec's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Evotec's Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.23) EPS, FY2026 earnings at $0.02 EPS and FY2027 earnings at $0.44 EPS.
Separately, Deutsche Bank Aktiengesellschaft raised Evotec from a "sell" rating to a "hold" rating in a report on Thursday, April 24th.
View Our Latest Stock Report on EVO
Evotec Trading Down 2.9%
Shares of EVO traded down $0.12 during trading hours on Monday, reaching $4.08. 340,175 shares of the company's stock traded hands, compared to its average volume of 134,120. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99. Evotec has a twelve month low of $2.84 and a twelve month high of $5.68. The business's fifty day simple moving average is $3.63 and its two-hundred day simple moving average is $4.17.
Institutional Investors Weigh In On Evotec
Several institutional investors have recently made changes to their positions in EVO. DCF Advisers LLC lifted its holdings in Evotec by 5.9% in the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock worth $956,000 after purchasing an additional 12,816 shares during the last quarter. BNP Paribas Financial Markets bought a new position in Evotec in the 4th quarter worth approximately $27,000. Bank of America Corp DE increased its position in Evotec by 262.5% in the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after buying an additional 9,289 shares during the period. Lighthouse Investment Partners LLC bought a new position in Evotec in the 4th quarter worth approximately $166,000. Finally, CSS LLC IL bought a new position in Evotec in the 4th quarter worth approximately $50,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Featured Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
